Computational evolutionary model to predict the efficacy of broadly neutralizing antibodies (bNAbs) in suppressing HIV and to design optimal combination therapy with bNAbs.

Drugs in a curative chemotherapy regimen are independently effective and resisted by different mechanisms, so cancer cells have little chance of surviving all drugs, and this benefit occurs without synergistic interactions.

A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.

In two independent cohorts, NNRTI-based cART regimens are associated with significantly lower cell-associated HIV RNA levels than PI-based regimens, suggesting more potent suppression of residual virus replication by NNRTI-based regimens.

The novel PDLIM2 nanomedicine enhances chemoimmunotherapy for complete cure of lung cancer.

A systematic review shows no evidence of harm or benefit of antibiotic combinations on resistance evolution as clinical data lack statistical power to draw definitive conclusions, highlighting a knowledge gap.

The functional relevance of stem cell niche perturbation in sarcomagenesis is defined and the mouse model presented provides a rationale for the use of combination therapy for the treatment of genetically heterogeneous sarcomas.

Models of malaria and treatment dynamics were combined with emulator-based global sensitivity analysis to elucidate the interplay between drug, biology, and epidemiological factors on the evolution of resistance to malaria treatments, including artemisinin.

Tregs form an "immunosuppressive ring" around solid tumors that is broken down during adoptive cell therapy and cyclophosphamide combination immunotherapy.

MIR20B has a deteriorating effect in NAFLD by suppressing PPARA, and may serve as a therapeutic target for combination therapy with fenofibrate for NAFLD.